Entera Bio (ENTX) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Entera Bio (ENTX) has outperformed REGENXBIO (RGNX) over the past year, gaining 32.8% versus a loss of 27.7%. Over five years, ENTX leads with a -44.5% price change compared with -78.9% for RGNX. REGENXBIO is the larger company by market cap ($534.0 million vs $434.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTX | RGNX |
|---|---|---|
| Share price | $2.50 | $8.09 |
| Market cap | $434.59M | $534.05M |
| 1-day change | -0.40% | +6.52% |
| YTD return | +29.38% | -47.26% |
| 1-year return | +32.80% | -27.74% |
| 5-year return | -44.47% | -78.87% |
| EPS (TTM) | $-0.36 | $-3.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.20 | $16.19 |
| 52-week low | $0.91 | $5.46 |
| Distance from 52-week high | -40.48% | -50.03% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +290.00% | +191.47% |
| Average volume | 1.82M | 1.52M |
| Shares outstanding | 173.83M | 66.01M |
| Employees | 20 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTX has outperformed RGNX by 60.5 percentage points over the past year.
About Entera Bio
ENTX stock →Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
ENTX vs RGNX FAQ
Which is bigger, Entera Bio or REGENXBIO?
REGENXBIO (RGNX) is larger, with a market capitalization of $534.05M compared with $434.59M for Entera Bio (ENTX).
Which stock has performed better over the past year, ENTX or RGNX?
ENTX returned +32.80% over the past 12 months, compared with -27.74% for RGNX (price return, excluding dividends). Past performance does not predict future results.
Are Entera Bio and REGENXBIO in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.